The Medical Briefing  Nephrology

Felzartamab in IgA nephropathy, SGLT2 inhibitors and GLP-1RA in kidney transplant recipients, ACHIEVE, GLP-1RA and kidney health

Retrospective no. 12/12

The essentials in four articles

■ Glomerular disease
54 patients with IgA nephropathy: proteinuria at 9 months −29.5% with 9 infusions of felzartamab vs −5.7% with placebo; effect maintained at 24 months (UPCR −44.5%). Adverse events mostly grade 1–2.

■ Transplantation
Meta-analysis in 7,834 kidney transplant recipients treated with SGLT2 inhibitors or GLP-1 receptor agonists: stable kidney function, no excess infections (SGLT2i) or pancreatitis (GLP-1RA).

■ CKD and dialysis
Spironolactone 25 mg per day in chronic hemodialysis: no reduction in the composite of cardiovascular death or hospitalization for heart failure; all-cause mortality HR 0.95 (95% CI 0.83–1.09).

■ CKD and dialysis
Spanish observational study (819 adults with type 2 diabetes, oral semaglutide, about 9 months): albuminuria −30 to −40%, stable GFR.